Visceral Leishmaniasis Treatment, Italy

Emerging Infectious Diseases

Volumn 9, Issue 12, 2003, Pages 1617-1620

  Gradoni, Luigi ^a   Gramiccia, Marina ^a   Scalone, Aldo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE;

ADULT; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; ITALY; LEISHMANIASIS; MAJOR CLINICAL STUDY; RELAPSE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; ZOONOSIS;

EID: 0345601046     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0912.030178     Document Type: Review

References (14)

1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43.
2. Mansueto S, Barba G, Cerrito B, Farinella E, Orsinis S, Di Rosa S. Visceral leishmaniasis of adults in Sicily: a truce interrupted? Trans R Soc Trop Med Hyg 1987;81:161-2.
3. Gradoni L. Epizootiology of canine leishmaniasis in southern Europe. In: R. Killick-Kendrick, editor. Canine leishmaniasis: an update. Proceedings of the Canine Leishmaniasis Forum, Barcelona, Spain. Wiesbaden, Germany: Hoechst Roussel Vet; 1999. p. 32-9.
4. Gradoni L, Scalone A, Gramiccia M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 1996;10:785-91.
5. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002;186:1366-70.
6. Gradoni L, Bryceson A, Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 1995;73:191-7.
7. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996;22:938-43.
8. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (lipsomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999;28:42-8.
9. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998;56:1009-18.
10. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800.
11. Cascio A, Gradoni L, Scarlata F, Gramiccia M, Giordano S, Russo R, et al. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. Am J Trop Med Hyg 1997;57:75-8.
12. Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992;86:61320.
13. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997;41:827-30.
14. Carrió J, Portús M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol 2002;2:11.